<DOC>
	<DOCNO>NCT03092154</DOCNO>
	<brief_summary>The use lipid lower agent patient idiopathic inflammatory myopathy controversial . Therefore , aim present study ass clinically laboratory impact lipid-lowering agent population .</brief_summary>
	<brief_title>Lipid-lowering Agents Patients With Dermatomyositis Polymyositis</brief_title>
	<detailed_description>Impact lipid lower agent patient dermatomyositis polymyositis .</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<criteria>fullfill criterion Bohan Peter ( 1975 ) dyslipidemia age &gt; 18 year prednisone ≤ 0.25 mg/kg/day ( ≤ 15mg/ ay ) last three month without change nutritional habit last three month , study period change lifestyle last three month , study period Patients : disease relapse overlap myositis neoplasia associate myositis diabetes mellitus current and/or chronic infection patient undergo major surgery within six month prior study pregnant patient previous use lipidlowering agent last 6 month use cyclosporin , erythromycin , clarithromycin , fibrates , niacin , azole antifungal , cimetidine , diltiazem active liver disease persistent elevation hepatic enzyme , apparent cause , exceed three time upper limit normality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>